Nitrase Therapeutics Expands Pipeline to Include Oncology Programs and Adds Seasoned Cancer Experts to Scientific Advisory Board
June 02, 2022 08:00 ET
|
Nitrase Therapeutics
BRISBANE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its unique NITROME platform to unlock the therapeutic potential of nitrases, a...
Nitrase Therapeutics Receives New Grant from The Michael J. Fox Foundation for Parkinson’s Research
April 05, 2022 08:00 ET
|
Nitrase Therapeutics
BRISBANE, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its unique NITROME platform to unlock the therapeutic potential of nitrases, a...
Nitrase Therapeutics Announces Major Discovery In Parkinson’s Disease Presented At The AD/PD International Conference
March 18, 2022 08:00 ET
|
Nitrase Therapeutics
-Company Identifies Potential New Biomarker And Diagnostic For Parkinson’s Disease- SAN FRANCISCO, March 18, 2022 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc. (formerly Nitrome Biosciences), a...
Nitrome Biosciences Appoints Pierre Beaurang, Ph.D., as Chief Executive Officer, Expands Series A to $45M, and Changes Company Name to Nitrase Therapeutics
November 02, 2021 08:00 ET
|
Nitrase Therapeutics
SAN FRANCISCO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc. (formerly Nitrome Biosciences), a biopharmaceutical company deploying its unique NITROME platform to unlock the...
Nitrome Biosciences Announces Formation of Scientific Advisory Board and Appointment of Former AbbVie Executive James Summers, Ph.D. to SAB Chairperson
November 12, 2020 16:00 ET
|
Nitrome Biosciences
SAN FRANCISCO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Nitrome Biosciences (Nitrome), a privately-held biopharmaceutical company developing a platform around its newly discovered class of enzymes to...
Nitrome Biosciences Appoints Industry Veteran Perry Karsen as Executive Chairman of the Board of Directors
October 13, 2020 08:00 ET
|
Nitrome Biosciences
SAN FRANCISCO, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Nitrome Biosciences (Nitrome), a privately-held biopharmaceutical company developing a platform around its newly discovered class of enzymes to...